{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:44:34Z","timestamp":1786146274347,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clbc.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:26:38Z","timestamp":1783628798000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Prognostic Utility of CPS+EG, Neo-Bioscore, and Conventional Staging Systems in Breast Cancer Patients Without Pathological Complete Response to Neoadjuvant Chemotherapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Tingting","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiju","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2984-1703","authenticated-orcid":false,"given":"Xi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10286","key":"10.1016\/j.clbc.2026.07.004_bib0001","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.clbc.2026.07.004_bib0002","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.004_bib0003","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/annonc\/mdz201","article-title":"The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine","volume":"30","author":"Loi","year":"2019","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2026.07.004_bib0004","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.1245\/s10434-025-18050-w","article-title":"The association of clinical stage at presentation with overall survival of patients who have HER2-positive breast cancer treated with neoadjuvant chemotherapy","volume":"32","author":"Tashjian","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.clbc.2026.07.004_bib0005","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jnci\/dji206","article-title":"American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome","volume":"97","author":"Carey","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"10.1016\/j.clbc.2026.07.004_bib0006","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clbc.2026.07.004_bib0007","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.2010.31.8469","article-title":"Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"29","author":"Mittendorf","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.004_bib0008","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/SLA.0000000000001492","article-title":"Combining clinical and pathologic staging variables has prognostic value in predicting local-regional recurrence following neoadjuvant chemotherapy for breast cancer","volume":"265","author":"Vila","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2026.07.004_bib0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2021.05.027","article-title":"Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy","volume":"153","author":"Marm\u00e9","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2026.07.004_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2015.09.022","article-title":"Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy","volume":"53","author":"Marm\u00e9","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2026.07.004_bib0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.breast.2018.03.010","article-title":"Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China","volume":"40","author":"Xu","year":"2018","journal-title":"Breast"},{"issue":"9712","key":"10.1016\/j.clbc.2026.07.004_bib0012","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.clbc.2026.07.004_bib0013","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.004_bib0014","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamaoncol.2015.6478","article-title":"The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment","volume":"2","author":"Mittendorf","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2026.07.004_bib0015","doi-asserted-by":"crossref","first-page":"114037","DOI":"10.1016\/j.ejca.2024.114037","article-title":"Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy","volume":"202","author":"Roussot","year":"2024","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.004_bib0016","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clbc.2026.07.004_bib0017","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"issue":"43","key":"10.1016\/j.clbc.2026.07.004_bib0018","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jncimonographs\/lgr037","article-title":"International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010)","volume":"2011","author":"Berruti","year":"2011","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.004_bib0019","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.004_bib0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.004_bib0021","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clbc.2026.07.004_bib0022","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.004_bib0023","first-page":"93","article-title":"The Eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.004_bib0024","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7093","article-title":"Prognosis after pathologic complete response to neoadjuvant therapy in early-stage breast cancer: a population-based study","volume":"23","author":"Boman","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clbc.2026.07.004_bib0025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10257","key":"10.1016\/j.clbc.2026.07.004_bib0026","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.004_bib0027","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:31:30Z","timestamp":1786145490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1526820926001072"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Prognostic Utility of CPS+EG, Neo-Bioscore, and Conventional Staging Systems in Breast Cancer Patients Without Pathological Complete Response to Neoadjuvant Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}